| Title |
Topical henna for capecitabine induced hand–foot syndrome
|
|---|---|
| Published in |
Investigational New Drugs, September 2007
|
| DOI | 10.1007/s10637-007-9082-3 |
| Pubmed ID | |
| Authors |
Idris Yucel, Gonullu Guzin |
| Abstract |
Capecitabine is a chemotherapeutic drug for use in cancers. Hand-foot syndrome (HFS) is side effect of capecitabine which can lead the cessation of the therapy or dose reduction. Henna (Lawsonia inermis) is a traditionally used plant of Middle-East that is applied on hands and feet. Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna. In these patients, six patients were grade 3 HFS and four were grade 2 HFS. Complete response (CR) were seen in four of grade 3 HFS and all of grade 2; two grade 3 HFS improved to grade 1. So far, in the chemotherapy, there was no need of dose reduction and also no side effect of henna seen. Clinical improvement in these patients may relate to anti-inflammatory, antipyretic and analgesic effects of henna. Prospective studies are needed to show this therapeutic effect of henna. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 21% |
| Student > Postgraduate | 3 | 11% |
| Professor > Associate Professor | 3 | 11% |
| Student > Master | 3 | 11% |
| Researcher | 2 | 7% |
| Other | 7 | 25% |
| Unknown | 4 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 32% |
| Biochemistry, Genetics and Molecular Biology | 4 | 14% |
| Agricultural and Biological Sciences | 3 | 11% |
| Nursing and Health Professions | 2 | 7% |
| Unspecified | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2022.
All research outputs
#4,323,333
of 24,631,014 outputs
Outputs from Investigational New Drugs
#144
of 1,242 outputs
Outputs of similar age
#12,020
of 74,201 outputs
Outputs of similar age from Investigational New Drugs
#4
of 13 outputs
Altmetric has tracked 24,631,014 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,242 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 74,201 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.